{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T06:01:41Z","timestamp":1792389701382,"version":"4.4.0"},"update-to":[{"DOI":"10.1002\/14651858.cd010965","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T00:00:00Z","timestamp":1530144000000}}],"reference-count":184,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010965.pub2","type":"journal-article","created":{"date-parts":[[2018,6,28]],"date-time":"2018-06-28T13:51:44Z","timestamp":1530193904000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Interventions for chronic non-hypovolaemic hypotonic hyponatraemia"],"prefix":"10.1002","volume":"2018","author":[{"given":"Evi V","family":"Nagler","sequence":"first","affiliation":[{"name":"Ghent University Hospital; Renal Division, Sector Metabolic and Cardiovascular Conditions; De Pintelaan 185 Ghent Belgium 9000"},{"name":"Guidance Body of the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA); European Renal Best Practice (ERBP); London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C","family":"Haller","sequence":"additional","affiliation":[{"name":"Guidance Body of the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA); European Renal Best Practice (ERBP); London UK"},{"name":"Medical University Vienna; Section for Clinical Biometrics, Center for Medical Statistics, Informatics and Intelligent Systems; Spitalgasse 23 Vienna Austria A-1090"},{"name":"Ordensklinikum Linz Elisabethinen; Department of Nephrology; Fadingerstra\u00dfe 1 Linz Austria 4020"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Van Biesen","sequence":"additional","affiliation":[{"name":"Ghent University Hospital; Renal Division, Sector Metabolic and Cardiovascular Conditions; De Pintelaan 185 Ghent Belgium 9000"},{"name":"Guidance Body of the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA); European Renal Best Practice (ERBP); London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond","family":"Vanholder","sequence":"additional","affiliation":[{"name":"Ghent University Hospital; Renal Division, Sector Metabolic and Cardiovascular Conditions; De Pintelaan 185 Ghent Belgium 9000"},{"name":"Guidance Body of the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA); European Renal Best Practice (ERBP); London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan C","family":"Craig","sequence":"additional","affiliation":[{"name":"The Children's Hospital at Westmead; Cochrane Kidney and Transplant, Centre for Kidney Research; Westmead NSW Australia 2145"},{"name":"The University of Sydney; Sydney School of Public Health; Edward Ford Building A27 Sydney NSW Australia 2006"},{"name":"Flinders University; College of Medicine and Public Health; Adelaide SA Australia 5001"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela C","family":"Webster","sequence":"additional","affiliation":[{"name":"The Children's Hospital at Westmead; Cochrane Kidney and Transplant, Centre for Kidney Research; Westmead NSW Australia 2145"},{"name":"The University of Sydney; Sydney School of Public Health; Edward Ford Building A27 Sydney NSW Australia 2006"},{"name":"The University of Sydney at Westmead; Centre for Transplant and Renal Research, Westmead Millennium Institute; Westmead NSW Australia 2145"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,6,28]]},"reference":[{"issue":"2 Suppl","key":"10.1002\/14651858.CD010965.pub2-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1067\/mhj.2003.154","article-title":"Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure","volume":"145","author":"Gheorghiade","year":"2003","journal-title":"American Heart Journal"},{"issue":"16","key":"10.1002\/14651858.CD010965.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1001\/jama.291.16.1963","article-title":"Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial","volume":"291","author":"Gheorghiade","year":"2004","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD010965.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1080\/17482940701210179","article-title":"Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial","volume":"9","author":"Rossi","year":"2007","journal-title":"Acute Cardiac Care"},{"issue":"1","key":"10.1002\/14651858.CD010965.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1097\/MAJ.0b013e31817b8148","article-title":"Efficacy and safety of oral conivaptan, a vasopressin-receptor antagonist, evaluated in a randomized, controlled trial in patients with euvolemic or hypervolemic hyponatremia","volume":"337","author":"Annane","year":"2009","journal-title":"American Journal of the Medical Sciences"},{"issue":"Abstracts","key":"10.1002\/14651858.CD010965.pub2-BIB0005|cit5","first-page":"43A","article-title":"Vasopressin V1A and V2 antagonist conivaptan increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure [abstract no: F-FC028]","volume":"16","author":"Ghali","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Oct","key":"10.1002\/14651858.CD010965.pub2-BIB0006|cit6","first-page":"353A","article-title":"Conivaptan, a novel V1a\/V2 antagonist, increases serum sodium and effective water clearance in hyponatremia [abstract no: SA-PO243]","volume":"15","author":"Gross","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"key":"10.1002\/14651858.CD010965.pub2-BIB0010|cit7","unstructured":"FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012 deals.bio\/home\/download?doc_id=911 1 217"},{"issue":"5","key":"10.1002\/14651858.CD010965.pub2-BIB0007|cit8","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/j.1752-8062.2010.00217.x","article-title":"Rationale and design of the treatment of hyponatremia based on lixivaptan in NYHA class III\/IV cardiac patient evaluation (THE BALANCE) study","volume":"3","author":"Abraham","year":"2010","journal-title":"Clinical & Translational Science"},{"key":"10.1002\/14651858.CD010965.pub2-BIB0008|cit9","unstructured":"Cardiokine Biopharma LLC Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio-Renal Drugs Advisory Committee Meeting www.wayback.archive-it.org\/7993\/20170404150420\/https:\/\/www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/CardiovascularandRenalDrugsAdvisoryCommittee\/UCM320625.pdf"},{"key":"10.1002\/14651858.CD010965.pub2-BIB0009|cit10","unstructured":"FDA Center for Drug Evaluation and Research A matter of record: Cardiovascular and Renal Drug Advisory Committee Meeting 13 September 2012 www.wayback.archive-it.org\/7993\/20170722221724\/https:\/\/www.fda.gov\/AdvisoryCommittees\/Calendar\/ucm313273.htm"},{"issue":"Abstracts","key":"10.1002\/14651858.CD010965.pub2-BIB0011|cit11","first-page":"38A","article-title":"Randomized, double-blind, placebo-controlled, parallel-group, multicenter study evaluating the efficacy and safety of satavaptan (SR121463B) in patients with SIADH [abstract no: F-FC007]","volume":"17","author":"Decaux","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD010965.pub2-BIB0012|cit12","first-page":"790A","article-title":"Satavaptan, a vasopressin V2-receptor antagonist, in the treatment of dilutional hyponatremia [abstract no: SU-PO928]","volume":"18","author":"Aronson","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD010965.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/eurjhf\/hfq226","article-title":"Short- and long-term treatment of dilutional hyponatraemia with satavaptan, a selective arginine vasopressin V2-receptor antagonist: the DILIPO study","volume":"13","author":"Aronson","year":"2011","journal-title":"European Journal of Heart Failure"},{"issue":"6","key":"10.1002\/14651858.CD010965.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/0003-4819-100-6-777","article-title":"Renal response to captopril in severe heart failure: role of furosemide in natriuresis and reversal of hyponatremia","volume":"100","author":"Dzau","year":"1984","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD010965.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1161\/CIRCOUTCOMES.110.958009","article-title":"Identifying patients hospitalized with heart failure at risk for unfavorable future quality of life","volume":"4","author":"Allen","year":"2011","journal-title":"Circulation. Cardiovascular Quality & Outcomes"},{"issue":"2","key":"10.1002\/14651858.CD010965.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ahj.2012.11.004","article-title":"Clinical profile and prognostic value of low systolic blood pressure in patients hospitalized for heart failure with reduced ejection fraction: insights from the Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST) trial","volume":"165","author":"Ambrosy","year":"2013","journal-title":"American Heart Journal"},{"issue":"20","key":"10.1002\/14651858.CD010965.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1016\/j.jacc.2008.07.056","article-title":"Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program","volume":"52","author":"Blair","year":"2008","journal-title":"Journal of the American College of Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD010965.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3111\/13696998.2011.643329","article-title":"Evaluation of costs associated with tolvaptan-mediated length-of-stay reduction among heart failure patients with hyponatremia in the US, based on the EVEREST trial","volume":"15","author":"Chiong","year":"2012","journal-title":"Journal of Medical Economics"},{"issue":"4","key":"10.1002\/14651858.CD010965.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2146\/ajhp100217","article-title":"Effect of serum sodium concentration and tolvaptan treatment on length of hospitalization in patients with heart failure","volume":"68","author":"Cyr","year":"2011","journal-title":"American Journal of Health-System Pharmacy"},{"issue":"10","key":"10.1002\/14651858.CD010965.pub2-BIB0020|cit20","first-page":"370e","article-title":"Evaluation of the hospital resource utilization associated with tolvaptan usage among heart failure patients with hyponatremia from the EVEREST trial [abstract]","volume":"31","author":"Dasta","year":"2011","journal-title":"Pharmacotherapy"},{"issue":"3","key":"10.1002\/14651858.CD010965.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"A38","DOI":"10.1016\/j.jval.2011.02.224","article-title":"Evaluation of the hospital resource utilization associated with tolvaptan usage among heart failure patients with hyponatremia from the EVEREST trial [abstract no: PCV36]","volume":"14","author":"Dasta","year":"2011","journal-title":"Value in Health"},{"issue":"12","key":"10.1002\/14651858.CD010965.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","article-title":"Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials","volume":"297","author":"Gheorghiade","year":"2007","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD010965.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.cardfail.2005.03.009","article-title":"Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST)","volume":"11","author":"Gheorghiade","year":"2005","journal-title":"Journal of Cardiac Failure"},{"issue":"6","key":"10.1002\/14651858.CD010965.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.cardfail.2013.04.001","article-title":"Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan","volume":"19","author":"Hauptman","year":"2013","journal-title":"Journal of Cardiac Failure"},{"issue":"12","key":"10.1002\/14651858.CD010965.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.297.12.1319","article-title":"Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial","volume":"297","author":"Konstam","year":"2007","journal-title":"JAMA"},{"issue":"3","key":"10.1002\/14651858.CD010965.pub2-BIB0026|cit26","first-page":"401","article-title":"Clinical profile and prognostic value of anemia at the time of admission and discharge among patients hospitalized for heart failure with reduced ejection fraction: findings from the EVEREST trial","volume":"7","author":"Mentz","year":"2014","journal-title":"Circulation: Heart Failure"},{"issue":"5","key":"10.1002\/14651858.CD010965.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.ahj.2010.02.023","article-title":"Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program.[Erratum appears in Am Heart J. 2012 May;163(5):900]","volume":"159","author":"O'Connor","year":"2010","journal-title":"American Heart Journal"},{"issue":"6","key":"10.1002\/14651858.CD010965.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.ahj.2011.02.027","article-title":"Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials","volume":"161","author":"Pang","year":"2011","journal-title":"American Heart Journal"},{"issue":"7","key":"10.1002\/14651858.CD010965.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2459\/JCM.0b013e328355a740","article-title":"Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment","volume":"13","author":"Vaduganathan","year":"2012","journal-title":"Journal of Cardiovascular Medicine"},{"issue":"Abstracts","key":"10.1002\/14651858.CD010965.pub2-BIB0030|cit30","first-page":"120A","article-title":"Difference in solute excretion after treatment of hyponatremia related to SIADH or cirrhosis by the non peptide, oral active selective vasopressin V2 receptor antagonist, vpa-985 [abstract]","volume":"10","author":"Decaux","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD010965.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1053\/gast.2003.50143","article-title":"Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: a randomized double-blind multicenter trial","volume":"124","author":"Gerbes","year":"2003","journal-title":"Gastroenterology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD010965.pub2-BIB0032|cit32","first-page":"121A","article-title":"Treatment of hyponatremia (hypo) with VPA-985 [abstract]","volume":"10","author":"Gross","year":"1999","journal-title":"Journal of the American Society of Nephrology"},{"issue":"4","key":"10.1002\/14651858.CD010965.pub2-BIB0033|cit33","first-page":"419A","article-title":"VPA-985, an orally active vasopressin receptor antagonist improves hyponatremia in patients with cirrhosis: a double-blind placebo controlled multicenter trial [abstract]","volume":"30","author":"Guelberg","year":"1999","journal-title":"Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD010965.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1210\/jc.2005-2287","article-title":"Efficacy and safety of oral conivaptan: a V1A\/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia","volume":"91","author":"Ghali","year":"2006","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"Abstracts","key":"10.1002\/14651858.CD010965.pub2-BIB0035|cit35","first-page":"43A","article-title":"Vasopressin V1A and V2 antagonist conivaptan increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure [abstract no: F-FC028]","volume":"16","author":"Ghali","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"21","key":"10.1002\/14651858.CD010965.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1161\/01.CIR.0000070422.41439.04","article-title":"Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial","volume":"107","author":"Gheorghiade","year":"2003","journal-title":"Circulation"},{"issue":"7","key":"10.1002\/14651858.CD010965.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.amjcard.2005.10.050","article-title":"Vasopressin v(2) receptor blockade with tolvaptan versus fluid restriction in the treatment of hyponatremia","volume":"97","author":"Gheorghiade","year":"2006","journal-title":"American Journal of Cardiology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD010965.pub2-BIB0038|cit38","first-page":"413A","article-title":"Effects of satavaptan on hyponatremia,management of ascites and morbidity in liver cirrhosis in a long-term placebo-controlled study [abstract]","volume":"48","author":"Gines","year":"2008","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD010965.pub2-BIB0042|cit39","unstructured":"FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012 deals.bio\/home\/download?doc_id=911 1 217"},{"issue":"11","key":"10.1002\/14651858.CD010965.pub2-BIB0039|cit40","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/ki.2012.274","article-title":"Oral lixivaptan effectively increases serum sodium concentrations in outpatients with euvolemic hyponatremia","volume":"82","author":"Abraham","year":"2012","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD010965.pub2-BIB0040|cit41","unstructured":"Cardiokine Biopharma LLC Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio-Renal Drugs Advisory Committee Meeting www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/CardiovascularandRenalDrugsAdvisoryCommittee\/UCM318869.pdf 1 61"},{"key":"10.1002\/14651858.CD010965.pub2-BIB0041|cit42","unstructured":"FDA Center for Drug Evaluation and Research A matter of record: Cardiovascular and renal drug advisory committee meeting 13 September 2012 www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/cardiovascularandrenaldrugsadvisorycommittee\/ucm345074.pdf 1 203"},{"issue":"10","key":"10.1002\/14651858.CD010965.pub2-BIB0043|cit43","first-page":"A1386","article-title":"Oral urea in the treatment of hyponatraemic ascites [abstract]","volume":"28","author":"Hayes","year":"1987","journal-title":"Gut"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD010965.pub2-BIB0044|cit44","first-page":"451A","article-title":"Improvement of hyponatremia in cirrhosis increases speed of complex information processing [abstract]","volume":"50","author":"Cordoba","year":"2009","journal-title":"Hepatology"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD010965.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"S270","DOI":"10.1016\/S0168-8278(06)80732-4","article-title":"Effects of satavaptan (SR121463B), a selective vasopressin V2 receptor antagonist, on serum sodium concentration and ascites in patients with cirrhosis and hyponatraemia [abstract]","volume":"44","author":"Gines","year":"2006","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD010965.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1002\/hep.22293","article-title":"Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial","volume":"48","author":"Gines","year":"2008","journal-title":"Hepatology"},{"issue":"6","key":"10.1002\/14651858.CD010965.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1053\/j.ajkd.2015.12.024","article-title":"Tolvaptan and neurocognitive function in mild to moderate chronic hyponatremia: a randomized trial (INSIGHT)","volume":"67","author":"Verbalis","year":"2016","journal-title":"American Journal of Kidney Diseases"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010965.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"S95","DOI":"10.1016\/S0168-8278(07)61830-3","article-title":"Albumin infusion for severe hyponatremia in patients with refractory ascites: a randomized clinical trial [abstract]","volume":"46","author":"Jalan","year":"2007","journal-title":"Journal of Hepatology"},{"issue":"7","key":"10.1002\/14651858.CD010965.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"590","DOI":"10.2146\/ajhp100243","article-title":"Effect of loading dose and formulation on safety and efficacy of conivaptan in treatment of euvolemic and hypervolemic hyponatremia","volume":"68","author":"Kalra","year":"2011","journal-title":"American Journal of Health-System Pharmacy"},{"issue":"9","key":"10.1002\/14651858.CD010965.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"818","DOI":"10.2146\/ajhp100260","article-title":"Efficacy and safety of 30-minute infusions of conivaptan in euvolemic and hypervolemic hyponatremia.[Erratum appears in Am J Health Syst Pharm. 2011 Aug 1;68(15):1374]","volume":"68","author":"Koren","year":"2011","journal-title":"American Journal of Health-System Pharmacy"},{"key":"10.1002\/14651858.CD010965.pub2-BIB0055|cit51","unstructured":"FDA briefing document for the Cardiovascular and Renal Drugs Advisory (CRDAC) 13 September 2012 news.medlive.cn\/uploadfile\/2012\/0523\/20120523095216110.pdf 1 217"},{"issue":"Abstracts","key":"10.1002\/14651858.CD010965.pub2-BIB0051|cit52","first-page":"3B","article-title":"Safety and efficacy of the vasopressin V2-receptor antagonist, lixivaptan, in outpatients with euvolemic hyponatremia [abstract no: LB-PO3144]","volume":"22","author":"Abraham","year":"2011","journal-title":"Journal of the American Society of Nephrology"},{"issue":"11","key":"10.1002\/14651858.CD010965.pub2-BIB0052|cit53","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1038\/ki.2012.275","article-title":"Lixivaptan safely and effectively corrects serum sodium concentrations in hospitalized patients with euvolemic hyponatremia","volume":"82","author":"Abraham","year":"2012","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD010965.pub2-BIB0053|cit54","unstructured":"Cardiokine Biopharma LLC Lixivaptan for the treatment of symptomatic euvolemic hyponatremia associated with syndrome of inappropriate antidiuretic hormone (SIADH) and symptomatic hypervolemic hyponatremia associated with heart failure. Advisory Committee Briefing Document. FDA Cardio-Renal Drugs Advisory Committee Meeting www.fda.gov\/downloads\/AdvisoryCommittees\/CommitteesMeetingMaterials\/Drugs\/CardiovascularandRenalDrugsAdvisoryCommittee\/UCM318869.pdf 1 61"},{"key":"10.1002\/14651858.CD010965.pub2-BIB0054|cit55","unstructured":"FDA Center for Drug Evaluation and Research A matter of record: Cardiovascular and renal drug advisory committee meeting 13 September 2012 www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/cardiovascularandrenaldrugsadvisorycommittee\/ucm345074.pdf 1 203"},{"issue":"1","key":"10.1002\/14651858.CD010965.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s12028-010-9379-5","article-title":"Use of Conivaptan (Vaprisol) for hyponatremic neuro-ICU patients.[Erratum appears in Neurocrit Care. 2011 Aug;15(1):210 Note: Leibling, Storm M [corrected to Liebling, Storm M]]","volume":"13","author":"Naidech","year":"2010","journal-title":"Neurocritical Care"},{"issue":"6","key":"10.1002\/14651858.CD010965.pub2-BIB0057|cit57","first-page":"341","article-title":"Moderate potentially drug-induced hyponatremia in older adults: benefit in drug reduction","volume":"68","author":"Peyro Saint Paul","year":"2013","journal-title":"Therapie"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010965.pub2-BIB0058|cit58","first-page":"74","article-title":"Benefit of pharmacological intervention on drug-induced mild hyponatremia in elderly: a prospective randomised trial [abstract no: P229]","volume":"26","author":"Peyro Saint Paul","year":"2012","journal-title":"Fundamental & Clinical Pharmacology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010965.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"S76","DOI":"10.1016\/S0168-8278(09)60184-7","article-title":"Effect of M0002, a novel V2 antagonist on sodium levels and weight gain affected by water accumulation in cirrhotic patients with ascites [abstract no: 182]","volume":"50","author":"Nevens","year":"2009","journal-title":"Journal of Hepatology"},{"issue":"12","key":"10.1002\/14651858.CD010965.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1002\/jcph.342","article-title":"Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH","volume":"54","author":"Chen","year":"2014","journal-title":"Journal of Clinical Pharmacology"},{"issue":"10","key":"10.1002\/14651858.CD010965.pub2-BIB0061|cit61","first-page":"936","article-title":"The efficacy and safety of tolvaptan on treating heart failure patients with hyponatremia","volume":"39","author":"Li","year":"2011","journal-title":"Chung-Hua Hsin Hsueh Kuan Ping Tsa Chih [Chinese Journal of Cardiology]"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD010965.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"A127","DOI":"10.1136\/heartjnl-2011-300867.368","article-title":"The efficacy and safety of tolvaptan on treating congestive heart failure patients with hyponatremia [abstract no: gw22-e0446]","volume":"97","author":"Ling","year":"2011","journal-title":"Heart"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD010965.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"A216","DOI":"10.1136\/heartjnl-2011-300867.635","article-title":"The efficacy and safety of tolvaptan on treating congestive heart failure patients with hyponatremia [abstract no: gw22-e0831]","volume":"97","author":"Ling","year":"2011","journal-title":"Heart"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD010965.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"S249","DOI":"10.1016\/S0168-8278(12)60641-2","article-title":"A multicenter, randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of tolvaptan on hyponatremia in Chinese cirrhotic patients [abstract]","volume":"56","author":"Jia","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD010965.pub2-BIB0065|cit65","first-page":"501","article-title":"A randomized, double blind, placebo-controlled trial of tolvaptan in hyponatremic patients with cancer [abstract]","volume":"61","author":"Ali","year":"2013","journal-title":"Journal of Investigative Medicine"},{"issue":"5","key":"10.1002\/14651858.CD010965.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/cncr.28468","article-title":"Tolvaptan in hospitalized cancer patients with hyponatremia: a double-blind, randomized, placebo-controlled clinical trial on efficacy and safety","volume":"120","author":"Salahudeen","year":"2014","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD010965.pub2-BIB0067|cit67","unstructured":"Bai S Targum S Thompson A Combined clinical and statistical review www.fda.gov\/ohrms\/dockets\/ac\/08\/briefing\/2008-4373b1-02.pdf 1 120"},{"issue":"4","key":"10.1002\/14651858.CD010965.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1681\/ASN.2009080857","article-title":"Oral tolvaptan is safe and effective in chronic hyponatremia.[Erratum appears in J Am Soc Nephrol. 2010 Aug;21(8):1407]","volume":"21","author":"Berl","year":"2010","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD010965.pub2-BIB0069|cit69","first-page":"S156","article-title":"Efficacy of tolvaptan in cancer patients with hyponatremia due to SIADH: post-hoc analysis of SALT (study of ascending levels of tolvaptan) [abstract]","volume":"22","author":"Blais","year":"2014","journal-title":"Supportive Care in Cancer"},{"issue":"3","key":"10.1002\/14651858.CD010965.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jhep.2011.08.020","article-title":"Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis","volume":"56","author":"Cardenas","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD010965.pub2-BIB0071|cit71","first-page":"467A","article-title":"The effects of a vasopressin V2 receptor antagonist in the management of patients with cirrhosis and hyponatremia. Safety and efficacy of oral tolvaptan in the SALT trials [abstract]","volume":"50","author":"Cardenas","year":"2009","journal-title":"Hepatology"},{"issue":"Suppl 12","key":"10.1002\/14651858.CD010965.pub2-BIB0072|cit72","first-page":"155","article-title":"Estimation of cost savings associated with tolvaptan-mediated length of stay (LOS) reduction among SIADH patients in the US, based on SALT-1 and SALT-2 trials [abstract no: 563]","volume":"39","author":"Dasta","year":"2011","journal-title":"Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD010965.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"A176","DOI":"10.1016\/j.jval.2012.03.956","article-title":"Evaluation of cost offset associated with tolvaptan usage among hyponatremic SIADH patients in the united states, based on the SALT-1 and SALT-2 trials [abstract]","volume":"15","author":"Dasta","year":"2012","journal-title":"Value in Health"},{"issue":"1","key":"10.1002\/14651858.CD010965.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3810\/hp.2012.02.942","article-title":"Evaluation of costs associated with tolvaptan-mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT-1 and SALT-2 trials","volume":"40","author":"Dasta","year":"2012","journal-title":"Hospital Practice (1995)"},{"issue":"12","key":"10.1002\/14651858.CD010965.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.biopsych.2008.06.017","article-title":"Double-blind, placebo-controlled, multicenter trial of a vasopressin V2-receptor antagonist in patients with schizophrenia and hyponatremia","volume":"64","author":"Josiassen","year":"2008","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD010965.pub2-BIB0076|cit76","unstructured":"Otsuka Pharmaceutical Development & Commercialization Treatment of hyponatremia: medical utility of vasopressin V2 receptor antagonism: briefing document www.fda.gov\/ohrms\/dockets\/ac\/08\/briefing\/2008-4373b1-05.pdf 1 131"},{"issue":"20","key":"10.1002\/14651858.CD010965.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa065181","article-title":"Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia","volume":"355","author":"Schrier","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD010965.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"A354","DOI":"10.1016\/j.jval.2014.08.746","article-title":"EQ-5D scores in patients receiving tolvaptan for the treatment of hyponatraemia secondary to the syndrome of inappropriate antidiuretic hormone secretion [abstract]","volume":"17","author":"Trueman","year":"2014","journal-title":"Value in Health"},{"issue":"7","key":"10.1002\/14651858.CD010965.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"A350","DOI":"10.1016\/j.jval.2014.08.728","article-title":"The cost-effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden [abstract]","volume":"17","author":"Trueman","year":"2014","journal-title":"Value in Health"},{"key":"10.1002\/14651858.CD010965.pub2-BIB0080|cit80","unstructured":"U.S. Food Drug Administration NDA 22-275: tolvaptan for the treatment of hypervolemic and euvolemic hyponatremia and for prevention of worsening hyponatremia FDA review of patient-reported outcome (PRO) measures for the hyponatremia indication www.fda.gov\/ohrms\/dockets\/ac\/08\/briefing\/2008-4373b1-03.pdf 1 7"},{"issue":"5","key":"10.1002\/14651858.CD010965.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1530\/EJE-10-1078","article-title":"Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion","volume":"164","author":"Verbalis","year":"2011","journal-title":"European Journal of Endocrinology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010965.pub2-BIB0082|cit82","first-page":"756A","article-title":"Randomized, placebo-controlled trial of tolvaptan, a novel v2-receptor antagonist, in hyponatremia: results of the SALT 2 trial with emphasis on efficacy and safety in cirrhosis [abstract]","volume":"42","author":"Afdhal","year":"2005","journal-title":"Hepatology"},{"key":"10.1002\/14651858.CD010965.pub2-BIB0083|cit83","unstructured":"Bai S Targum S Thompson A Combined clinical and statistical review www.fda.gov\/ohrms\/dockets\/ac\/08\/briefing\/2008-4373b1-02.pdf 1 120"},{"issue":"4","key":"10.1002\/14651858.CD010965.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1681\/ASN.2009080857","article-title":"Oral tolvaptan is safe and effective in chronic hyponatremia.[Erratum appears in J Am Soc Nephrol. 2010 Aug;21(8):1407]","volume":"21","author":"Berl","year":"2010","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1 Suppl 1","key":"10.1002\/14651858.CD010965.pub2-BIB0085|cit85","first-page":"S156","article-title":"Efficacy of tolvaptan in cancer patients with hyponatremia due to SIADH: Post-hoc analysis of SALT (study of ascending levels of tolvaptan) [abstract]","volume":"22","author":"Blais","year":"2014","journal-title":"Supportive Care in Cancer"},{"issue":"3","key":"10.1002\/14651858.CD010965.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jhep.2011.08.020","article-title":"Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis","volume":"56","author":"Cardenas","year":"2012","journal-title":"Journal of Hepatology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD010965.pub2-BIB0087|cit87","first-page":"467","article-title":"The effects of a vasopressin V2 receptor antagonist in the management of patients with cirrhosis and hyponatremia. Safety and efficacy of oral tolvaptan in the SALT trials [abstract]","volume":"50","author":"Cardenas","year":"2009","journal-title":"Hepatology"},{"issue":"Suppl 12","key":"10.1002\/14651858.CD010965.pub2-BIB0088|cit88","first-page":"155","article-title":"Estimation of cost savings associated with tolvaptan-mediated length of stay (LOS) reduction among SIADH patients in the US, based on SALT-1 and SALT-2 trials [abstract no: 563]","volume":"39","author":"Dasta","year":"2011","journal-title":"Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD010965.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"A176","DOI":"10.1016\/j.jval.2012.03.956","article-title":"Evaluation of cost offset associated with tolvaptan usage among hyponatremic SIADH patients in the united states, based on the SALT-1 and SALT-2 trials [abstract]","volume":"15","author":"Dasta","year":"2012","journal-title":"Value in Health"},{"issue":"1","key":"10.1002\/14651858.CD010965.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3810\/hp.2012.02.942","article-title":"Evaluation of costs associated with tolvaptan-mediated hospital length of stay reduction among US patients with the syndrome of inappropriate antidiuretic hormone secretion, based on SALT-1 and SALT-2 trials","volume":"40","author":"Dasta","year":"2012","journal-title":"Hospital Practice (1995)"},{"issue":"12","key":"10.1002\/14651858.CD010965.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.biopsych.2008.06.017","article-title":"Double-blind, placebo-controlled, multicenter trial of a vasopressin V2-receptor antagonist in patients with schizophrenia and hyponatremia","volume":"64","author":"Josiassen","year":"2008","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD010965.pub2-BIB0092|cit92","unstructured":"Otsuka Pharmaceutical Development & Commercialization Treatment of hyponatremia: medical utility of vasopressin V2 receptor antagonism: briefing document www.fda.gov\/ohrms\/dockets\/ac\/08\/briefing\/2008-4373b1-05.pdf 1 131"},{"issue":"20","key":"10.1002\/14651858.CD010965.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1056\/NEJMoa065181","article-title":"Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia","volume":"355","author":"Schrier","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD010965.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"A354","DOI":"10.1016\/j.jval.2014.08.746","article-title":"EQ-5D scores in patients receiving tolvaptan for the treatment of hyponatraemia secondary to the syndrome of inappropriate antidiuretic hormone secretion [abstract]","volume":"17","author":"Trueman","year":"2014","journal-title":"Value in Health"},{"issue":"7","key":"10.1002\/14651858.CD010965.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"A350","DOI":"10.1016\/j.jval.2014.08.728","article-title":"The cost-effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden [abstract]","volume":"17","author":"Trueman","year":"2014","journal-title":"Value in Health"},{"key":"10.1002\/14651858.CD010965.pub2-BIB0096|cit96","unstructured":"U.S. Food Drug Administration NDA 22-275: tolvaptan for the treatment of hypervolemic and euvolemic hyponatremia and for prevention of worsening hyponatremia. FDA review of patient-reported outcome (PRO) measures for the hyponatremia indication www.fda.gov\/ohrms\/dockets\/ac\/08\/briefing\/2008-4373b1-03.pdf 1 7"},{"issue":"5","key":"10.1002\/14651858.CD010965.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1530\/EJE-10-1078","article-title":"Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion","volume":"164","author":"Verbalis","year":"2011","journal-title":"European Journal of Endocrinology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010965.pub2-BIB0098|cit98","first-page":"S88","article-title":"Low-dose tolvaptan PK\/PD: Comparison of subjects with hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion (SIADH) to healthy adults [abstract]","volume":"101","author":"Shoaf","year":"2017","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"11","key":"10.1002\/14651858.CD010965.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1007\/s00228-017-2302-7","article-title":"Low-dose tolvaptan PK\/PD: comparison of patients with hyponatremia due to syndrome of inappropriate antidiuretic hormone secretion to healthy adults","volume":"73","author":"Shoaf","year":"2017","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"6","key":"10.1002\/14651858.CD010965.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1097\/00006454-199506000-00006","article-title":"Fluid restriction does not improve the outcome of acute meningitis","volume":"14","author":"Singhi","year":"1995","journal-title":"Pediatric Infectious Disease Journal"},{"issue":"Oct","key":"10.1002\/14651858.CD010965.pub2-BIB0101|cit101","first-page":"563A","article-title":"Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with SR121463B, an orally active, nonpeptide, vasopressin V2-receptor antagonist [abstract no: SU-PO0140]","volume":"15","author":"Soupart","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD010965.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.2215\/CJN.00160106","article-title":"Successful long-term treatment of hyponatremia in syndrome of inappropriate antidiuretic hormone secretion with satavaptan (SR121463B), an orally active nonpeptide vasopressin V2-receptor antagonist","volume":"1","author":"Soupart","year":"2006","journal-title":"Clinical Journal of the American Society of Nephrology: CJASN"},{"issue":"1","key":"10.1002\/14651858.CD010965.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1053\/jhep.2003.50021","article-title":"A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: a multicenter, randomized, placebo-controlled trial","volume":"37","author":"Wong","year":"2003","journal-title":"Hepatology"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD010965.pub2-BIB0104|cit104","first-page":"A221","article-title":"Evaluation of tolvaptan in the treatment of hyponatremia in chronic heart failure patient [abstract]","volume":"99","author":"Yang","year":"2013","journal-title":"Heart"},{"issue":"Abstracts","key":"10.1002\/14651858.CD010965.pub2-BIB0105|cit105","first-page":"43A","article-title":"Vasopressin V1A and V2 antagonist conivaptan increased serum sodium concentration in patients with hyponatremia secondary to congestive heart failure [abstract no: F-FC028]","volume":"16","author":"Ghali","year":"2005","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts Issue","key":"10.1002\/14651858.CD010965.pub2-BIB0106|cit106","first-page":"790A","article-title":"Efficacy and safety of the vasopressin-receptor antagonist conivaptan hydrochloride injection in the treatment of hypervolemic hyponatremia [abstract no: SU-PO929]","volume":"18","author":"Goldsmith","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Abstracts","key":"10.1002\/14651858.CD010965.pub2-BIB0107|cit107","first-page":"356A","article-title":"Novel vasopressin V1a and V2 antagonist conivaptan increases serum sodium concentration and effective water clearance in hyponatremia [abstract no: SA-PO254]","volume":"15","author":"Verbalis","year":"2004","journal-title":"Journal of the American Society of Nephrology"},{"issue":"18 Suppl","key":"10.1002\/14651858.CD010965.pub2-BIB0108|cit108","first-page":"480","article-title":"Efficacy and safety of the vasopressin antagonist conivaptan in patients with euvolemic hyponatremia evaluated in a phase III clinical trial [abstract]","volume":"24","author":"Verbalis","year":"2006","journal-title":"Journal of Clinical Oncology"},{"issue":"4 Suppl","key":"10.1002\/14651858.CD010965.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"562S","DOI":"10.1378\/chest.132.4_MeetingAbstracts.562b","article-title":"Efficacy and safety of conivaptan, a vasopressin v1a- and v2-receptor antagonist, during phase 3 trials of patients with euvolemic or hypervolemic hyponatremia [abstract]","volume":"132","author":"Verbalis","year":"2007","journal-title":"Chest"},{"issue":"1","key":"10.1002\/14651858.CD010965.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/j.1365-2265.2007.03149.x","article-title":"Assessment of the efficacy and safety of intravenous conivaptan in patients with euvolaemic hyponatraemia: subgroup analysis of a randomized, controlled study","volume":"69","author":"Verbalis","year":"2008","journal-title":"Clinical Endocrinology"},{"issue":"5","key":"10.1002\/14651858.CD010965.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1159\/000106456","article-title":"Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia","volume":"27","author":"Zeltser","year":"2007","journal-title":"American Journal of Nephrology"},{"issue":"8","key":"10.1002\/14651858.CD010965.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1016\/j.jacc.2005.11.071","article-title":"Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients","volume":"47","author":"Abraham","year":"2006","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"10.1002\/14651858.CD010965.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cardfail.2012.11.007","article-title":"A randomized controlled pilot study of outcomes of strict allowance of fluid therapy in hyponatremic heart failure (SALT-HF)","volume":"19","author":"Albert","year":"2013","journal-title":"Journal of Cardiac Failure"},{"issue":"4","key":"10.1002\/14651858.CD010965.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/0006-3223(91)90300-B","article-title":"A double blind, placebo-controlled trial of demeclocycline treatment of polydipsia-hyponatremia in chronically psychotic patients","volume":"30","author":"Alexander","year":"1991","journal-title":"Biological Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD010965.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/gut.2008.176495","article-title":"Combined versus sequential diuretic treatment of ascites in non-azotaemic patients with cirrhosis: Results of an open randomised clinical trial","volume":"59","author":"Angeli","year":"2010","journal-title":"Gut"},{"issue":"3","key":"10.1002\/14651858.CD010965.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1600-0676.1993.tb00624.x","article-title":"Efficacy and safety of the stepped care medical treatment of ascites in liver cirrhosis: a randomized controlled clinical trial comparing two diets with different sodium content","volume":"13","author":"Bernardi","year":"1993","journal-title":"Liver"},{"key":"10.1002\/14651858.CD010965.pub2-BIB0117|cit117","unstructured":"De Vita S Quartuccio L Isola M Masolini P Sacco S De Marchi G A randomized, controlled, multicenter phase III study of the efficacy and safety of rituximab (RTX) monotherapy versus the best available treatment in patients with mixed cryoglobulinemia syndrome [abstract] Arthritis & Rheumatism 2010 2201"},{"key":"10.1002\/14651858.CD010965.pub2-BIB0118|cit118","doi-asserted-by":"crossref","unstructured":"De Vita S Quartuccio L Isola M Mazzaro C Scaini P Lenzi M A randomized controlled trial of rituximab for the treatment of severe cryoglobulinemic vasculitis Arthritis & Rheumatism 2012 843 53 22147661","DOI":"10.1002\/art.34331"},{"key":"10.1002\/14651858.CD010965.pub2-BIB0119|cit119","unstructured":"De Vita S Quartuccio L Masolini P Stefania S De Marchi G Zabotti A A randomized, controlled, multicenter phase III study of the efficacy and safety of rituximab (RTX) monotherapy versus the best available treatment (BAT) in patients with mixed cryoglobulinemia syndrome [abstract no: OP0120] Annals of Rheumatic Diseases 2010 93"},{"key":"10.1002\/14651858.CD010965.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jaut.2015.07.012","article-title":"Retreatment regimen of rituximab monotherapy given at the relapse of severe HCV-related cryoglobulinemic vasculitis: Long-term follow up data of a randomized controlled multicentre study","volume":"63","author":"Quartuccio","year":"2015","journal-title":"Journal of Autoimmunity"},{"key":"10.1002\/14651858.CD010965.pub2-BIB0121|cit121","doi-asserted-by":"crossref","unstructured":"Quartuccio L Zuliani F Corazza L Scaini P Zani R Lenzi M Rituximab monotherapy of severe HCV-related cryoglobulinemic vasculitis for more than 2 years: follow-up of a randomized controlled multicentre study [abstract no: OP0228] Annals of the Rheumatic Diseases 2014","DOI":"10.1136\/annrheumdis-2014-eular.3872"},{"issue":"3","key":"10.1002\/14651858.CD010965.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s12028-011-9525-8","article-title":"Open-label randomized trial of the safety and efficacy of a single dose conivaptan to raise serum sodium in patients with traumatic brain injury","volume":"14","author":"Galton","year":"2011","journal-title":"Neurocritical Care"},{"issue":"6","key":"10.1002\/14651858.CD010965.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1093\/eurjhf\/hfs051","article-title":"The efficacy and safety of lixivaptan in outpatients with heart failure and volume overload: results of a multicentre, randomized, double-blind, placebo-controlled, parallel-group study","volume":"14","author":"Ghali","year":"2012","journal-title":"European Journal of Heart Failure"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010965.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/S0168-8278(07)61688-2","article-title":"Long-term improvement of serum sodium by the V2-receptor antagonist satavaptan in patients with cirrhosis and hyponatraemia [abstract]","volume":"46","author":"Gines","year":"2007","journal-title":"Journal of Hepatology"},{"issue":"5","key":"10.1002\/14651858.CD010965.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1053\/jhep.2002.36375","article-title":"Pharmacodynamic effects of a nonpeptide antidiuretic hormone V2 antagonist in cirrhotic patients with ascites","volume":"36","author":"Guyader","year":"2002","journal-title":"Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD010965.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1253\/circj.CJ-17-0179","article-title":"Effects of additive tolvaptan vs. increased furosemide on heart failure with diuretic resistance and renal impairment- results from the K-STAR study","volume":"82","author":"Inomata","year":"2017","journal-title":"Circulation Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010965.pub2-BIB0127|cit127","first-page":"659","article-title":"Effect of additive tolvaptan versus increased furosemide on refractory heart failure with renal impairment: Results from the K-STAR study [abstract no: P3742]","volume":"36","author":"Inomata","year":"2015","journal-title":"European Heart Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010965.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"i175","DOI":"10.1093\/ndt\/gfw164.08","article-title":"Significance of serum sodium concentration in the very early treatment phase of congestive heart failure complicated by advanced chronic kidney disease: Posthoc analysis of the K-STAR study [abstract]","volume":"31","author":"Tominaga","year":"2016","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD010965.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1067\/mhj.2003.166","article-title":"Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects","volume":"145","author":"Licata","year":"2003","journal-title":"American Heart Journal"},{"key":"10.1002\/14651858.CD010965.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1007\/s10557-011-6303-y","article-title":"Effects of tolvaptan on volume overload in Japanese patients with heart failure: results of a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study","volume":"25 Suppl 1","author":"Matsuzaki","year":"2011","journal-title":"Cardiovascular Drugs & Therapy"},{"key":"10.1002\/14651858.CD010965.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1007\/s10557-011-6304-x","article-title":"Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: A phase III, randomized, double-blind, placebo-controlled study (QUEST study)","volume":"25 Suppl 1","author":"Matsuzaki","year":"2011","journal-title":"Cardiovascular Drugs & Therapy"},{"issue":"1","key":"10.1002\/14651858.CD010965.pub2-BIB0132|cit132","first-page":"39","article-title":"Hypervolemic therapy with fludrocortisone acetate for brain protection from cerebral vasospasm caused by subarachnoid hemorrhage","volume":"41","author":"Mori","year":"1999","journal-title":"Nihon University Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD010965.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/hepr.12099","article-title":"Dose-finding trial of tolvaptan in liver cirrhosis patients with hepatic edema: a randomized, double-blind, placebo-controlled trial","volume":"44","author":"Okita","year":"2014","journal-title":"Hepatology Research"},{"issue":"10","key":"10.1002\/14651858.CD010965.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s00535-015-1052-5","article-title":"Can serum albumin level affect the pharmacological action of tolvaptan in patients with liver cirrhosis? A post hoc analysis of previous clinical trials in Japan","volume":"50","author":"Sakaida","year":"2015","journal-title":"Journal of Gastroenterology"},{"issue":"5","key":"10.1002\/14651858.CD010965.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jsams.2013.09.001","article-title":"Efficacy of oral versus intravenous hypertonic saline in runners with hyponatremia","volume":"17","author":"Owen","year":"2014","journal-title":"Journal of Science & Medicine in Sport"},{"issue":"3","key":"10.1002\/14651858.CD010965.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S1388-9842(00)00094-5","article-title":"Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refractory congestive heart failure","volume":"2","author":"Paterna","year":"2000","journal-title":"European Journal of Heart Failure"},{"issue":"7","key":"10.1002\/14651858.CD010965.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"416","DOI":"10.4103\/0019-5049.160943","article-title":"Effectiveness of single dose conivaptan for correction of hyponatraemia in post-operative patients following major head and neck surgeries","volume":"59","author":"Rajan","year":"2015","journal-title":"Indian Journal of Anaesthesia"},{"issue":"10","key":"10.1002\/14651858.CD010965.pub2-BIB0138|cit138","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1185\/03007998809111119","article-title":"An open comparative study of two diuretic combinations, frusemide\/amiloride ('Frumil') and bumetanide\/potassium chloride ('Burinex' K), in the treatment of congestive cardiac failure in hospital out-patients","volume":"10","author":"Ramsay","year":"1988","journal-title":"Current Medical Research & Opinion"},{"issue":"3","key":"10.1002\/14651858.CD010965.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/JSM.0b013e31821a6450","article-title":"An intervention study of oral versus intravenous hypertonic saline administration in ultramarathon runners with exercise-associated hyponatremia: a preliminary randomized trial","volume":"21","author":"Rogers","year":"2011","journal-title":"Clinical Journal of Sport Medicine"},{"issue":"1","key":"10.1002\/14651858.CD010965.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/hepr.12098","article-title":"Tolvaptan for improvement of hepatic edema: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial","volume":"44","author":"Sakaida","year":"2014","journal-title":"Hepatology Research"},{"issue":"10","key":"10.1002\/14651858.CD010965.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1007\/s00535-015-1052-5","article-title":"Can serum albumin level affect the pharmacological action of tolvaptan in patients with liver cirrhosis? A post hoc analysis of previous clinical trials in Japan","volume":"50","author":"Sakaida","year":"2015","journal-title":"Journal of Gastroenterology"},{"issue":"1","key":"10.1002\/14651858.CD010965.pub2-BIB0142|cit142","first-page":"147","article-title":"Efficacy and safety of rapid intermittent correction compared with slow continuous correction with hypertonic saline in patients with moderately severe or severe symptomatic hyponatremia: study protocol for a randomized controlled trial (SALSA trial)","volume":"18","author":"Lee","year":"2017","journal-title":"Trials [Electronic Resource]"},{"issue":"5","key":"10.1002\/14651858.CD010965.pub2-BIB0143|cit143","first-page":"997","article-title":"Tolvaptan in patients hospitalized with acute heart failure: rationale and design of the TACTICS and the SECRET of CHF trials","volume":"8","author":"Felker","year":"2015","journal-title":"Circulation: Heart Failure"},{"issue":"11","key":"10.1002\/14651858.CD010965.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.jacc.2016.12.035","article-title":"Short-term effects of tolvaptan in patients with acute heart failure and volume overload","volume":"69","author":"Konstam","year":"2017","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD010965.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.ihj.2015.07.006","article-title":"Effect of tolvaptan on acute heart failure with hyponatremia - a randomized, double blind, controlled clinical trial","volume":"68 Suppl 1","author":"Shanmugam","year":"2016","journal-title":"Indian Heart Journal"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010965.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1093\/eurheartj\/eht309.P3316","article-title":"Acute heart failure volume control trial: The comparison of tolvaptan and carperitide [abstract]","volume":"34","author":"Suzuki","year":"2013","journal-title":"European Heart Journal"},{"issue":"12","key":"10.1002\/14651858.CD010965.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1002\/jcph.197","article-title":"Acute Heart Failure Volume Control Multicenter Randomized (AVCMA) Trial: comparison of tolvaptan and carperitide","volume":"53","author":"Suzuki","year":"2013","journal-title":"Journal of Clinical Pharmacology"},{"issue":"5","key":"10.1002\/14651858.CD010965.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.jjcc.2015.09.020","article-title":"Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure","volume":"67","author":"Kimura","year":"2016","journal-title":"Journal of Cardiology"},{"issue":"5","key":"10.1002\/14651858.CD010965.pub2-BIB0149|cit149","first-page":"997","article-title":"Tolvaptan in patients hospitalized with acute heart failure: rationale and design of the TACTICS and the SECRET of CHF trials","volume":"8","author":"Felker","year":"2015","journal-title":"Circulation: Heart Failure"},{"issue":"11","key":"10.1002\/14651858.CD010965.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/j.jacc.2016.09.004","article-title":"Efficacy and safety of tolvaptan in patients hospitalized with acute heart failure","volume":"69","author":"Felker","year":"2017","journal-title":"Journal of the American College of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD010965.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1111\/j.1365-2036.2006.03088.x","article-title":"Oral V2 receptor antagonist (RWJ-351647) in patients with cirrhosis and ascites: a randomized, double-blind, placebo-controlled, single ascending dose study","volume":"24","author":"Thuluvath","year":"2006","journal-title":"Alimentary Pharmacology & Therapeutics"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD010965.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"S42","DOI":"10.1016\/S0168-8278(09)60104-5","article-title":"Effects of Satavaptan, an oral vasopressin V2 receptor antagonist, on management of ascites and morbidity in liver cirrhosis in a long-term, placebo-controlled study [abstract]","volume":"50","author":"Wong","year":"2009","journal-title":"Journal of Hepatology"},{"issue":"2","key":"10.1002\/14651858.CD010965.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jhep.2010.02.036","article-title":"Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis","volume":"53","author":"Wong","year":"2010","journal-title":"Journal of Hepatology"},{"issue":"1","key":"10.1002\/14651858.CD010965.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1136\/gutjnl-2011-300157","article-title":"Satavaptan for the management of ascites in cirrhosis: efficacy and safety across the spectrum of ascites severity","volume":"61","author":"Wong","year":"2012","journal-title":"Gut"},{"issue":"11","key":"10.1002\/14651858.CD010965.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1136\/gut.2010.210732","article-title":"Association of the G-protein and alpha2-adrenergic receptor gene and plasma norepinephrine level with clonidine improvement of the effects of diuretics in patients with cirrhosis with refractory ascites: a randomised clinical trial","volume":"59","author":"Yang","year":"2010","journal-title":"Gut"},{"issue":"5","key":"10.1002\/14651858.CD010965.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1093\/ndt\/gfq565","article-title":"Effect of furosemide on left ventricular mass in non-dialysis chronic kidney disease patients: a randomized controlled trial","volume":"26","author":"Zamboli","year":"2011","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD010965.pub2-BIB0157|cit157","first-page":"141A","article-title":"Do COX-2 inhibitors induce more hyponatremia than non-selective NSAIDs? [abstract]","volume":"12","author":"Zellweger","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"21","key":"10.1002\/14651858.CD010965.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1056\/NEJM200005253422107","article-title":"Hyponatremia","volume":"342","author":"Adrogue","year":"2000","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD010965.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1681\/ASN.2012020128","article-title":"The challenge of hyponatremia","volume":"23","author":"Adrogue","year":"2012","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD010965.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.maturitas.2013.02.007","article-title":"Diuretic-induced hyponatremia and osteoporotic fractures in patients admitted to the emergency department","volume":"75","author":"Arampatzis","year":"2013","journal-title":"Maturitas"},{"issue":"12","key":"10.1002\/14651858.CD010965.pub2-BIB0161|cit161","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006254.pub2","article-title":"Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients","author":"Ballinger","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"20","key":"10.1002\/14651858.CD010965.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1056\/NEJMcp066837","article-title":"Clinical practice. The syndrome of inappropriate antidiuresis","volume":"356","author":"Ellison","year":"2007","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD010965.pub2-BIB0163|cit163","unstructured":"US Food Drug Administration FDA briefing document for the Cardiovascular and Renal Drug Advisory (CRDAC) - Drug: Lixivaptan www.fda.gov\/downloads\/advisorycommittees\/committeesmeetingmaterials\/drugs\/cardiovascularandrenaldrugsadvisorycommittee\/ucm318867.pdf"},{"issue":"7650","key":"10.1002\/14651858.CD010965.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010965.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1016\/j.jclinepi.2010.09.011","article-title":"GRADE guidelines: A new series of articles in the Journal of Clinical Epidemiology","volume":"64","author":"Guyatt","year":"2010","journal-title":"Journal of Clinical Epidemiology"},{"issue":"7414","key":"10.1002\/14651858.CD010965.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD010965.pub2-BIB0167|cit167","unstructured":"Higgins JP Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"8","key":"10.1002\/14651858.CD010965.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1002\/jbmr.380","article-title":"Mild hyponatremia as a risk factor for fractures: the Rotterdam study","volume":"26","author":"Hoorn","year":"2011","journal-title":"Journal of Bone & Mineral Research"},{"issue":"10","key":"10.1002\/14651858.CD010965.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"977.e1","DOI":"10.1016\/j.amjmed.2011.04.028","article-title":"Short-term efficacy and safety of vasopressin receptor antagonists for treatment of hyponatremia","volume":"124","author":"Jaber","year":"2011","journal-title":"American Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD010965.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2215\/CJN.06120809","article-title":"Hyponatremia independent of osteoporosis is associated with fracture occurrence","volume":"5","author":"Kinsella","year":"2010","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"3","key":"10.1002\/14651858.CD010965.pub2-BIB0171|cit171","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/ndt\/gfr428","article-title":"Osmotic diuresis due to urea as the cause of hypernatraemia in critically ill patients","volume":"27","author":"Lindner","year":"2012","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD010965.pub2-BIB0172|cit172","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.MR000033.pub3","article-title":"Industry sponsorship and research outcome","author":"Lundh","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD010965.pub2-BIB0173|cit173","unstructured":"Mirski D (Otsuka America Pharmaceutical Inc) Potential risk of liver injury with use of SAMSCA\u00ae (tolvaptan) www.sefap.it\/web\/upload\/UCM336675.pdf"},{"issue":"71","key":"10.1002\/14651858.CD010965.pub2-BIB0174|cit174","first-page":"e1","article-title":"Mild chronic hyponatremia is associated with falls, unsteadiness and attention deficits","volume":"119","author":"Renneboog","year":"2006","journal-title":"American Journal of Medicine"},{"issue":"7543","key":"10.1002\/14651858.CD010965.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/bmj.332.7543.702","article-title":"Disorders of sodium balance","volume":"332","author":"Reynolds","year":"2006","journal-title":"BMJ"},{"issue":"2","key":"10.1002\/14651858.CD010965.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1053\/j.ajkd.2010.01.013","article-title":"Vasopressin receptor antagonists for the treatment of hyponatremia: systematic review and meta-analysis","volume":"56","author":"Rozen-Zvi","year":"2010","journal-title":"American Journal of Kidney Diseases"},{"key":"10.1002\/14651858.CD010965.pub2-BIB0177|cit177","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010965.pub2-BIB0178|cit178","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Deeks JJ Glasziou P Guyatt GH Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD010965.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"i1","DOI":"10.1093\/ndt\/gfu040","article-title":"Clinical practice guideline on diagnosis and treatment of hyponatraemia.[Erratum appears in Nephrol Dial Transplant. 2014 Jun;40(6):924]","volume":"29","author":"Spasovski","year":"2014","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD010965.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.semnephrol.2009.03.004","article-title":"Epidemiology of hyponatremia","volume":"29","author":"Upadhyay","year":"2009","journal-title":"Seminars in Nephrology"},{"issue":"3","key":"10.1002\/14651858.CD010965.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1359\/jbmr.090827","article-title":"Hyponatremia-induced osteoporosis","volume":"25","author":"Verbalis","year":"2010","journal-title":"Journal of Bone & Mineral Research"},{"issue":"10 Suppl 1","key":"10.1002\/14651858.CD010965.pub2-BIB0182|cit182","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.amjmed.2013.07.006","article-title":"Diagnosis, evaluation, and treatment of hyponatremia: Expert panel recommendations","volume":"126","author":"Verbalis","year":"2013","journal-title":"American Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD010965.pub2-BIB0183|cit183","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1001\/archinternmed.2009.513","article-title":"Impact of hospital-associated hyponatremia on selected outcomes","volume":"170","author":"Wald","year":"2010","journal-title":"Archives of Internal Medicine"},{"issue":"2","key":"10.1002\/14651858.CD010965.pub2-BIB0184|cit184","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010965","article-title":"Interventions for chronic non-hypovolaemic hypotonic hyponatraemia","author":"Nagler","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD010965.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T22:50:41Z","timestamp":1628549441000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD010965.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Kidney and Transplant Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2018,6,28]]},"references-count":184,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2018,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010965.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,28]]}}}